| Methods | n = 61, 4 centres Allocation concealment: not described Baseline similarity: age, SAPS II, sepsis Blinding: caregivers Cointerventions: not described Withdrawals: none Losses to follow‐up: none |
|
| Participants | Inclusions: Risk factor and mild‐moderate ALI (lung injury score between 0.1 and 2.5) Exclusions: Cardiogenic pulmonary edema; immunocompromised |
|
| Interventions | Continuous IV NAC, 40 mg/kg/day for 3 days (total dose 120 mg/kg), or placebo | |
| Outcomes | 1 month mortality: RR 0.63 (95% CI 0.28 to 1.45) Adverse events attributed to study medication: none |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.